ALS Therapy Development Institute
  • HOME
  • RESEARCH CENTER
  • ALS COMMUNITY
  • SUPPORT US
  • ABOUT US
  • DONATE
  • Our Team
  • Board of Directors
  • History
  • Annual Reports
  • News
  • Funds
Login Register

ALS-TDI in the News

News and stories about ALS TDI from external media outlets.

  • The Wall Street Journal, "Dilemma: When 1 Drug Treats 2 Diseases"
  • Mass High Tech, "ALS Therapy nonprofit launches first Phase 2 drug trial"
  • BioTuesdays, "Non-profit ALS group readying Phase 2 trial"
  • MDA/ALS Newsmagazine, "ALS TDI to Test Multiple Sclerosis Drug in ALS"
  • Bio.org, "Podcast: Dr. Steve Perrin, ALS Therapy Development Institute"
  • WBUR's Here & Now, "A New Face For Lou Gehrig’s Disease"
  • Nature Genetics, "The rugged landscape of drug design"

Media Contact

Mari Sullivan
Public Relations Manager
617-441-7220
msullivan@als.net

About ALS TDI

  • Corporate Brochure and Mission Statement
  • Selected Short Videos
  • Take a Virtual Lab Tour
  • Annual Reports

Find this useful?
Help us fund more science:

Donate Now

Follow Us

Monthly Newsletter

Subscribe

Support Us

  • Donate Now
  • Why Support Us
  • How To Support
  • News & Media

What is ALS?

  • What Is ALS?

About ALS TDI

  • About Us
  • Our History
  • Our Team

Upcoming Events

  • 05/21 2nd Annual LOUYAA Baseball Club Golf Tournament
  • 04/26 Dick Sanderson D4L
  • 04/28 For Pete’s Sake!
  • 04/28 Jason Becker: Not Dead Yet (IFFB)

© 2012 ALS TDI

  • Contact Us
  • Privacy Policy
  • Terms & Conditions
  • SecurityMetrics for PCI Compliance, QSA, IDS, Penetration Testing, Forensics, and Vulnerability Assessment
ALS TDI is a 501(c)(3) registered nonprofit organization.